Daily Judi: Monday, January 9, 2023
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
On Friday, the United States Food and Drug Administration approved lecanemab, an Alzheimer’s drug developed by Eisai and Biogen, which in clinical trials slowed cognitive decline in the early stages of Alzheimer’s. The drug will be marketed under the name Leqembi, and administered every two weeks. (NBC News)
Meanwhile, Reuters looks at Eisai's pricing for the new Alzheimer’s drug.
Sabah Meddings examines the purchase by Huma Therapeutics of Alcedis, a clinical trials specialist, for over $24 million. (Bloomberg)
Helen Leask reviews several active clinical research trials investigating new treatments for lymphoma and leukemia. (Medscape)
Our Culture
“Dossiers and redaction are built within the Judi platform, which helps significantly with adjudication management—and the client collaborates on the process.”
–Jess, Program Manager
About Judi
Judi speeds and improves the world's clinical trial workflows. Our cloud-based platform has 120,000 users across 168 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 Type II certified collaboration platform.
